Previous 10 | Next 10 |
The following healthcare companies have filed prospectuses for mixed shelf offerings: More news on: Genprex, Inc., Syros Pharmaceuticals, Inc., ChromaDex Corporation, Healthcare stocks news, , Read more ...
Emerging victorious in a bidding joust with AcelRx Pharmaceuticals (NASDAQ: ACRX ), Melinta Therapeutics (NASDAQ: MLNT ) enters into a definitive merger agreement with Tetraphase Pharmaceuticals (NASDAQ: TTPH ) under which it will acquire the company for $39M in cash plus an additional $16...
Merger activity increased last week with one new deal announced, three deals closing and two deals called off. While two terminated deals in one week is a lot, the news was not all bad as one of those terminations was because the company received a better offer. Just when we thought the bidd...
AcelRx Pharmaceuticals (NASDAQ: ACRX ) announces that it does not intend to revise its latest cash-and-stock bid for Tetraphase Pharmaceuticals (NASDAQ: TTPH ) and expects the termination of their previously announced merger agreement since the latter's board deemed a competing offer f...
REDWOOD CITY, Calif. , June 3, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it does...
REDWOOD CITY, Calif. , June 1, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will b...
Tetraphase Pharmaceuticals ( TTPH -11.1% ) has entered into a second amendment of its merger agreement with AcelRx Pharmaceuticals ( ACRX ) after the latter submitted a revised bid of $0.5872 in cash plus 0.7409 in ACRX stock, representing an offer of ~$1.70 per share ($37M), topping Mel...
Signaling its determination to close the deal amid rival offers, AcelRx Pharmaceuticals ( ACRX -4.0% ) has increased its bid for Tetraphase Pharmaceuticals ( TTPH -8.3% ) to $30M in cash and stock plus an additional $14.5M in cash payable under a contingent value right (CVR). More news...
REDWOOD CITY, Calif. , May 27, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (AcelRx) (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of ...
On May 11 after the market closed, AcelRx Pharmaceuticals (NASDAQ: ACRX ) reported 1Q20 earnings. The stock did not move much from the event, but investors that have been following the company for some time now finally got a piece of news they had been waiting for. ACRX is a specialty phar...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...